A case to answer

Every now and again something intriguing comes along, which generates a flurry of interest from our…

February 17, 2021

What happens when genomics, KRAS, and IO converge in lung cancer?

Genomic analysis in IO trials is on the increase - what happens when PD-1 and KRAS collide?

February 2, 2021

Buildings walls versus building cathedrals

The devil is in the finer details...

October 27, 2020

New developments in the KRAS landscape

An update on two very different targets in the broader KRAS niche, one of which may have a particularly long lasting impact on the landscape.

October 15, 2020

Controversial developments in pancreatic cancer

What can we understand from novel research on the biology of the disease that might lead us to new cancer therapeutics?

July 30, 2020

What’s the skinny on a new IO target in oncology R&D?

A new emerging IO target of interest caught out attention, now what?

July 28, 2020

A new dawn for epigenetic therapy in oncology

A novel epigenetic target may have far-reaching outcomes for cancer patients

July 23, 2020

New developments in CAR-T cell therapies including controversial ones

The ups and downs of CAR-T cell therapy development continues apace

July 8, 2020

Reflections on the latest lurbinectedin and abemaciclib developments

What can we learn from the recent announcements for lurbinectedin in 2L SCLC and the CDK4/6 inhibitors in adjuvant HR+HER2- early breast cancer.

June 17, 2020

Solid tumour winners and losers at ASCO20

Highlights from several solid tumour trials in both early and late stage disease.

June 9, 2020

Can we add fire to the immune system with TIGIT?

A look at Genentech's tiragolumab (anti-TIGIT) in advanced lung cancer

June 1, 2020

One swallow does not a summer make

Why you should be wary of the hype surrounding the Iovance TIL data in NSCLC at AACR20

April 27, 2020

Reflections on new developments in the KRAS niche

Beyond KRAS G12C inhibitors, there are plenty of other related targets to consider including KRAS::SOS1 and SHP2

April 20, 2020

Impact of Covid–19 on Cancer Conferences

A look at the revised schedule and timelines for upcoming Spring cancer conference season

April 13, 2020

Will bromodomain inhibitors and PROTACs make an impact?

A look at BET-bromodomain inhibitors, PROTACs, stapled proteins and more on MYC

September 4, 2019

Novel DDR combinations and regimens that could make a difference

Latest preclinical and clinical news and readouts as well as forthcoming trial presentations to look forward to in the DDR space

August 16, 2019
Lightning bolt

Is the BMS CheckMate-227 trial a hit or miss in lung cancer?

Our latest analysis of the ever evolving NSCLC landscape following BMS’s announcement on CheckMate-227

July 25, 2019
Cambridge from Bay Bay Boston

An in-depth look at Neon’s updated neoantigen vaccine data

Insights on the updated phase 1b clinical data evaluating Neon's personalized vaccine NEO-PV-01 in combination with nivolumab in advanced cancers?

July 17, 2019

Ever decreasing circles in oncology R&D

Analysis and predictions of two oncology phase 3 readouts coming soon...

February 4, 2019

An update on key SCLC trials

A look at the CheckMate-331 and CheckMate-451 study and other SCLC trials

October 12, 2018

An early cell therapy product to watch out for

Cell therapy is a very broad church - here's an interesting approach to keep an eye on

September 19, 2018

New Insights on BCMA BiTEs and CAR T cell therapies in Myeloma

Update on BCMA, SLAMF7 and other targets in multiple myeloma

September 11, 2018

ASCO18 Reader Q&A

It’s a Bank Holiday weekend on both sides of the pond, which is always a good excuse for some…

May 25, 2018

Why we should be cautious about IO-IO combination trials

A look at some of the issues underlying IO-IO combos and whether they can help us assess if these trials will succeed - or not.

February 28, 2018

SCLC – An in-depth look at ROVA-T and TRINITY

A look at ROVA-T's chances in the upcoming phase 2 TRINITY trial readout

October 25, 2017


A look at the trials and tribulations for Immune Design's CMB305 and what's the latest in 1L NSCLC

October 20, 2017

$PBYI – plain sailing or death by a thousand cuts?

A look at the FDA briefing docs on Puma's neratinib

May 23, 2017

On Kite’s cerebral edema and Genentech’s IMvigor211 miss

We've been overdue a correction in the irrational exuberance around IO... is this the tip of the iceberg?

May 10, 2017

BSB Mailbag on ROS1, ALK and TRK inhibitors

BSB Reader Mailbag on TRK/ROS1/ALK inhibitors

April 28, 2017

Asking Good Questions is both an Art and a Science

Latest BSB reader Q&A looks at 5 questions from subscribers

March 16, 2017

On APHINITY, SOLO2 and Immunomedics

Reader Q&A on women's cancers relating to HER2, PARP and TNBC...

February 13, 2017

Can we expect more surprises in 1L NSCLC?

A look at the how several major phase 3 trial readouts will affect the 1L NSCLC landscape

January 18, 2017

September BSB Reader Mailbag

Latest BSB mailbag covers targeted therapies, immunotherapy and #ESMO16

September 29, 2016

Biotech Mailbag – Jounce & the CAR T Race to Market

July Reader Q&A - thoughts on Jounce, Celgene, BMS, J&J and CAR T cell therapies...

July 27, 2016

Reader Mailbag – TCR T cell Gene Editing in Multiple Myeloma

Gene editing is coming to the US CAR T cell space - what's happening and what will the impact be?

June 17, 2016

Biotech Strategy Blog Mailbag Monday

Subscriber questions on recent immuno-oncology, Genentech, Kite Pharma and Gilead company news

March 21, 2016

Q&A on hot topics in CAR T cell therapies

Our latest Q&A based on reader questions - In the Hot Spot: On CAR T cell therapies

November 18, 2015

Biotech Strategy questions answered on BRAF, MEK, immunotherapy, mirvetuximab soravtansine and venetoclax

This month's Biotech Strategy Blog mail bag.

July 17, 2015

Biotech Strategy questions answered on neratinib, bavituximab, enzalutamide and more!

Insights on targeted therapies from ASCO - questions from subs on neratinib, bavituximab, enzalutamide, Gilead's pipeline and MDSCs...

June 17, 2015